About Triana Biomedicines
Triana Biomedicines is a private company based in Lexington, Massachusetts. It has reported $178,611,967 raised in four offerings on Form D since July 2020.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Nov 26, 2025 | Dec 4, 2025 | $120,061,960fully sold | 20 | $6.0M | EquityRule 506(b) | Form D ↗ |
| Jan 28, 2022 | Feb 11, 2022amended Apr 19, 2022 | $42,550,007of $85.1M target | 14 | $3.0M | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Sep 3, 2021 | Sep 17, 2021 | $10,000,000fully sold | 1 | $10.0M | EquityRule 506(b) | Form D ↗ |
| May 22, 2020 | Jul 6, 2020 | $6,000,000of $14.0M target | 3 | $2.0M | EquityRule 506(b) | Form D ↗ |
| Total, four offerings | $178,611,967 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Triana Biomedicines's Form D filed Dec 4, 2025.
PT
Patrick Trojer
President and director
JR
Joshua Resnick
Director
JR
Jigar Raythatha
Director
DG
David Grayzel
Director
AH
Andrew Hedin
Director
LK
Lorence Kim
Director
SC
Shelley Chu
Director
Earlier filings also listed Simon Read (director, last listed Apr 2022), Milind Deshpande (director, last listed Apr 2022), Christopher O'Donnel (director, last listed Apr 2022), Nathaniel Brooks Horwitz (director, last listed Jul 2020) and Andrew Levin (director, last listed Jul 2020).